Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aegerion Pharma Inc (AEGR)

Aegerion Pharma Inc (AEGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aegerion Pharma Inc One Main Street Suite 800 Cambridge MA 02142

www.aegerion.com P: 617-500-7867

Description:

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 55,250
Shares Outstanding, K 29,540
Annual Sales, $ 239,890 K
Annual Net Income, $ -73,340 K
Last Quarter Sales, $ 35,390 K
Last Quarter Net Income, $ -26,570 K
60-Month Beta 0.50
% of Insider Shareholders 4.60%
% of Institutional Shareholders 84.87%

Growth:

1-Year Return -81.17%
3-Year Return -97.06%
5-Year Return -88.35%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -79.09%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.37 on 11/03/16
Latest Earnings Date 11/14/16
Earnings Per Share ttm -4.07
EPS Growth vs. Prev Qtr 47.13%
EPS Growth vs. Prev Year -757.14%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AEGR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -287.50%
Return-on-Assets % -30.75%
Profit Margin % -30.57%
Debt/Equity 95.58
Price/Sales 0.23
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.43
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar